Path MD INC

Path MD INC was paid $8.20M by Medicaid between Jan 2018 and Nov 2024, across 37 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 65% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#81 of 561

Median peer was paid$222K

This provider vs. median37×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,660	$156K
2019	5,207	$201K
2020	8,717	$541K
2021	55,052	$2.22M
2022	72,715	$2.97M
2023	32,408	$1.77M
2024incomplete	8,498	$337K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	65%	91,542	47,362	$5.35M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	11%	12,292	4,130	$933K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.3%	41,200	19,841	$438K
88305	Level IV - Surgical pathology, gross and microscopic examination	4.2%	6,730	6,162	$345K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	3.0%	1,027	1,007	$248K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.8%	2,960	2,865	$144K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	1.6%	7,904	3,304	$128K
88312		1.1%	2,689	2,556	$90K
88313		<1%	2,357	2,233	$74K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	3,636	927	$63K
87481		<1%	1,295	1,243	$49K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	1,342	1,339	$34K

25 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,224	$31K
87486		<1%	1,087	$27K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,220	$25K
87581		<1%	1,088	$25K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,234	$23K
87511		<1%	1,048	$22K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	490	$21K
88112		<1%	904	$21K
88344		<1%	281	$20K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	302	$19K
88342		<1%	639	$17K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	145	$17K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,315	$10K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	141	$7K
88341		<1%	148	$4K
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method	<1%	42	$3K
87500		<1%	202	$3K
87640		<1%	239	$3K
87641		<1%	203	$2K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	54	$2K
87653		<1%	139	$1K
87563		<1%	67	$872.36
87529		<1%	35	$724.34
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	22	$216.78
88304		<1%	14	$163.32

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTABIB, SIAMAK (OWNER)